Results 91 to 100 of about 1,660 (124)

Bile Acid Metabolism as a Unifying Readout for Diet, Microbiome Function, and Gastrointestinal Disease

open access: yesThe FASEB Journal, Volume 40, Issue 17, 15 September 2026.
Dietary components shape the gut microbiome, which modifies bile acids through transformations. The resulting bile acid pool is sensed by host receptors to regulate immunity, metabolism, and intestinal function. Targeted bile acid measurements provide a unifying readout to study diet‐microbiome interactions and to develop next‐generation dietary ...
Jason Dichter
wiley   +1 more source

The G Protein-Coupled Bile Acid Receptor TGR5 (Gpbar1) Modulates Endothelin-1 Signaling in Liver

open access: yesCells, 2019
TGR5 (Gpbar1) is a G protein-coupled receptor responsive to bile acids (BAs), which is expressed in different non-parenchymal cells of the liver, including biliary epithelial cells, liver-resident macrophages, sinusoidal endothelial cells (LSECs), and ...
Caroline Klindt   +9 more
doaj   +1 more source

Decreased Expression of TGR5 in Vogt-Koyanagi-Harada (VKH) Disease

open access: yes, 2019
Purpose: To investigate the role of G-protein-coupled bile acid receptor-1, Gpbar1 (TGR5) in the pathogenesis of Vogt-Koyanagi-Harada (VKH) disease. Methods: The mRNA level of TGR5, iNOS, Arg1, CD16, and CD206 in macrophages was assayed by real-time PCR.
Lin, Meng   +21 more
core   +1 more source

The Receptor TGR5 Mediates the Prokinetic Actions of Intestinal Bile Acids and Is Required for Normal Defecation in Mice [PDF]

open access: yes, 2013
BACKGROUND & AIMS: Abnormal delivery of bile acids (BAs) to the colon as a result of disease or therapy causes constipation or diarrhea by unknown mechanisms.
Schoonjans, Kristina   +19 more
core   +1 more source

TGR5-dependent hepatoprotection through the regulation of biliary epithelium barrier function

open access: yes, 2019
International audienceObjective We explored the hypothesis that TGR5, the bile acid (BA) G-protein-coupled receptor highly expressed in biliary epithelial cells, protects the liver against BA overload through the regulation of biliary epithelium ...
Rainteau, Dominique   +18 more
core   +1 more source

Sodium butyrate regulates macrophage polarization by TGR5/β-arrestin2 in vitro

open access: yesMolecular Medicine
Background Macrophages play an important role in the pathogenesis of ulcerative colitis (UC). We will explore the effects of sodium butyrate (SB) on macrophage function.
Miao Liu   +5 more
doaj   +1 more source

Bile acid signaling in skeletal muscle homeostasis: from molecular mechanisms to clinical applications

open access: yesFrontiers in Endocrinology
The intricate relationship between bile acid metabolism and skeletal muscle function has emerged as a crucial area of research in metabolic health. This review synthesizes current evidence highlighting the fundamental role of bile acids as key signaling ...
Feng Jia, Xiangliang Liu, Yahui Liu
doaj   +1 more source

The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders

open access: yes, 2013
TGR5 is the G-protein–coupled bile acid-activated receptor, found in many human and animal tissues. Considering different endocrine and paracrine functions of bile acids, the current review focuses on the role of TGR5 as a novel pharmacological target in
V. Stepanov (23379001)   +2 more
core   +2 more sources

Machine learning and molecular dynamics simulations predict potential TGR5 agonists for type 2 diabetes treatment

open access: yesFrontiers in Chemistry
IntroductionTreatment of type 2 diabetes (T2D) remains a significant challenge because of its multifactorial nature and complex metabolic pathways. There is growing interest in finding new therapeutic targets that could lead to safer and more effective ...
Ojochenemi A. Enejoh   +8 more
doaj   +1 more source

Clinical relevance of the bile acid receptor TGR5 in metabolism

open access: yes, 2017
The bile acid receptor TGR5 (also known as GPBAR1) is a promising target for the development of pharmacological interventions in metabolic diseases, including type 2 diabetes, obesity, and non-alcoholic steatohepatitis.
Scheltema, Matthijs J   +13 more
core   +1 more source

Home - About - Disclaimer - Privacy